Dynavax Names Timothy Henn, Vice President, Finance & Administration
BERKELEY, Calif., Aug. 24 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today announced the appointment of Timothy Henn, to the position of Vice President, Finance and Administration.
Mr. Henn comes to Dynavax from Incyte Corporation where he was most recently Senior Vice President, Finance and Corporate Controller, having responsibility for company wide accounting, financial planning, and purchasing. He brings over 20 years of experience in accounting and finance, and has been instrumental in numerous strategic, financial and operational activities.
"Tim's track record in managing all aspects of the controllership and administrative functions in the public company environment will assist Dynavax in maintaining effective financial planning, strong internal controls and support services," said Dino Dina, M.D., president and chief executive officer of Dynavax. With Tim on board, we can focus our search for a chief financial officer that can complement his role in areas such as corporate and financing strategy, as well as investor relations."
About Dynavax
Dynavax Technologies Corporation discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Our clinical development programs are based on immunostimulatory sequences, or ISS, which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. ISS are being developed in three separate indications: a ragweed allergy program, a Hepatitis B vaccine program in late stage clinical development, and an asthma program that just completed a Phase II exploratory trial.
Dynavax cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Dynavax that any of its plans will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Dynavax's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; its ability to obtain additional financing to support its operations; its ability to maintain effective financial planning and internal controls; and other risks detailed in the "Risk Factors" section of Dynavax's Annual Report on Form 10-K filed on March 30, 2004, and in the section titled "Additional Factors That May Affect Future Results" within Dynavax's quarterly report on Form 10-Q filed on August 9, 2004. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Dynavax undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof.
SOURCE Dynavax Technologies Corporation
-0- 08/24/2004
/CONTACT: Dino Dina, M.D., President and Chief Executive Officer of
Dynavax Technologies Corporation, +1-510-848-5100/
/Web site: http://www.dynavax.com /
(DVAX)
CO: Dynavax Technologies Corporation
ST: California
IN: HEA MTC BIO
SU: PER
MP-MW
-- SFTU032 --
2161 08/24/2004 06:00 EDT http://www.prnewswire.com